Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda

November 5, 2024

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Gen Cancer Biotherapeutics

November 5, 2024

AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings

November 5, 2024

Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals

November 5, 2024

Revitope Enters into a License Agreement with Genmab for Next-gen T Cell Engagement Technology

November 5, 2024

Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Gen ADC Platform

November 5, 2024

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

November 5, 2024

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

November 5, 2024

Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture

October 29, 2024

AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings

October 29, 2024

Modifi Biosciences Acquired by Merck

October 29, 2024

Telix to Spin Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals

October 29, 2024

Sanofi and Orano join forces to develop next-generation radioligand medicines

October 22, 2024

ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a MSA for n.c.a. Lutetium-177

October 22, 2024

AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors

October 22, 2024

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

October 22, 2024

Actineer, a Joint Venture of ITM and CNL, Begins Actinium-225 Production

October 22, 2024

Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology

October 22, 2024

Nona Biosciences announced a strategic collaboration with OverT Bio to develop next-generation cell therapies for solid tumors

October 15, 2024

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into 1L HCC Pivotal Trial

October 15, 2024

Exelixis and Merck to Evaluate Zanzalintinib in Combination With KEYTRUDA in Head and Neck Cancer and in Combination With WELIREG in RCC

October 15, 2024

Ono Enters into License Agreement for LCB97 to generate novel ADC candidates by leveraging ConjuAll™ ADC platform with LigaChem Biosciences

October 15, 2024

Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib

October 15, 2024

MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy

October 15, 2024

Bayer and MOMA Therapeutics enter collaboration and license agreement in Oncology

October 15, 2024
Page1 … Page5 Page6 Page7 Page8 Page9 … Page26

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.